European Equity pre-Market Summary - 24th August 2026: potential Shell asset sale

M&A Shell (SHEL LN), -0.5%: Has drawn interest from potential bidders including ExxonMobil (XOM) and LyondellBasell (LYB) for its USD 8bln US chemicals assets sale, according to the FT citing sources. The figure, if correct, is seen as a steep discount. Pharmaceutical GSK (GSK LN): FDA has accepted priority review for Jemperli in dMMR/MSI-H locally advanced rectal cancer; PDUFA date is Feb 2027. Seperately, Japan approves Hibsago for chronic hepatitis B, marking its first global approval. Broker Moves Segro (SGRO LN): upgraded to Equal Weight from Underweight at Barclays Diploma (DPLM LN), +0.5%: upgraded to Overweight from Neutral at JPMorgan Sandvik (SAND SS), +1.5%: upgraded to Buy from Hold by SEB % after the Co. name and ticker are the pre-market indication via Tradegate